DoctrBenway
Posted - 1 day ago
$ADAP Alina Monakhova, speaking on Fierce Cell and Gene Therapy symposium, just now, indicated that they're working with $GLPG to decrease T-Cell manufacturing TAT to 7 days! (Decentralizing manufacturing.)
jackcoltrain
Posted - 6 days ago
$GLPG $QURE $SPRB $LOGC better than a savings account
CanadianMoose529
Posted - 6 days ago
@alex12345678910 None other than $GLPG
Fingerlickengood
Posted - 1 week ago
$ADAP $GLPG needs to just buy this entire company…CEO is worthless.
Fingerlickengood
Posted - 1 week ago
$ADAP yes, and this specifically catches my interest from $GLPG recent earnings: ” to continue to fund our proprietary pipeline and pursue select, value-enhancing deals.“ Bullish
Fingerlickengood
Posted - 1 week ago
$ADAP ADP-600 I could see another pharma company taking this under their wing for development like $GLPG did with uza-cel for head and neck cancer. https://synapse.patsnap.com/drug/eb7847acec47460b9d0b8e2adf92e74e#overview
Fingerlickengood
Posted - 1 week ago
$ADAP $GLPG ....breast cancer is one of the leading topics of cancer research, if PRAME is found to effectively treat patients without radiation and/or surgery will be a game changer!
Fingerlickengood
Posted - 1 week ago
$GLPG $ADAP
Fingerlickengood
Posted - 1 week ago
@Whtmtn haha...not wishing for a buyout, but illustrating their financial strength as a partner. Considering future earnings once lete-cel goes commercial of $440M annually, I don't think $GLPG could offer less than $1B right now even if they wanted to buyout $ADAP.
Fingerlickengood
Posted - 1 week ago
$ADAP $GLPG from Galapagos’ recent earnings, ”We are exploring strategic partnerships, early-stage research collaborations, licensing, and bolt-on acquisitions in areas of high unmet medical need to accelerate our cell therapy and small molecule pipeline in oncology and immunology.” … Financial guidance “As of September 30, 2024, we have €3.3 billion in cash and current financial investments to continue to fund our proprietary pipeline and pursue select, value-enhancing deals. We reiterate our cash burn guidance, including business development year-to-date, for the full year 2024, which is expected to be in the range of €370 million to €410 million.”
Fingerlickengood
Posted - 1 week ago
$ADAP i also believe $GLPG may have paid the $85M payment due for uza-cel…their 3rd qtr numbers were down per their latest earnings, which I believe may be part of the reason. Adrian said that the $15M upfront payment had been received and the $85M faculty payment was coming due during the Jeffries podcast in Augus, so hopefully it’s been made, cashed and showing accountable as income in Q3!
Fingerlickengood
Posted - 1 week ago
$ADAP $GLPG Lete-cel update hopefully tomorrow with an earnings surprise!
Fingerlickengood
Posted - 1 week ago
$GLPG $ADAP sorry..copy and pasted the wrong seminar…this is the one! Sponsored symposium: TECELRA® (afamitresgene autoleucel;'afami-cel') Cell Therapy for Treatment of Eligible Adults with MAGE-A4+ Synovial Sarcoma. Hosted by Sandra D'Angelo, M.D., Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center. Scheduled for Thursday, November 14th, 6:30 PM PST.
Fingerlickengood
Posted - 1 week ago
$ADAP $GLPG Interesting....Melissa Herman of Adaptimune is presenting the Lete-cel results at CTOS later this week, then presenting the Uza-cel results for Galapogos at ASH first week Dec: American Society of Hematology (ASH) 66th Annual Meeting, December 7-10, San Diego, CA Poster presentation: "Preclinical Proof of Concept for Decentralized Manufacturing of a MAGE-A4/CD8α-Expressing Autologous T-Cell Therapy for Solid Tumors" / Melissa Herman, PhD., Associate Director – Pipeline Research, Adaptimmune (with Galapagos). Scheduled for Saturday, December 7, 2024, 5:30 – 7:30 PM PST. https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/276/adaptimmune-to-participate-in-scientific-and-medical
Fingerlickengood
Posted - 1 week ago
$JNJ $RHHBY $PFE This PR posted for $GLPG mid-last week but clearly entails $ADAP uza-cel clinical and co-development data that will be presented in San Diego in couple weeks! Good stuff!
Fingerlickengood
Posted - 1 week ago
$ADAP $GLPG T- and TCR T-cell therapy pipeline at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 7-10 December 2024. Three abstracts, including one oral presentation, will feature new data from our proprietary cell therapy programs in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), and R/R chronic lymphocytic leukemia (CLL) and Richter transformation (RT), in addition to preclinical data in head & neck (H&N) cancer, developed in partnership with Adaptimmune. Galapagos will also host a company showcase, titled: Fresh, Fit, and Fast: Pioneering the Future of Cell Therapy through Decentralized Manufacturing. https://finance.yahoo.com/news/galapagos-present-results-pioneering-innovation-210100601.html
Fingerlickengood
Posted - 1 week ago
$ADAP It appears that they have now have 'eight' TECELRA treatment centers up and running! As I recall, I believe they indicated 5-7 by earnings....VERY NICE to see them moving this along! tecelra.com/patient/ATC $GLPG $JNJ $PFE $RHHBY
Fingerlickengood
Posted - 1 week ago
$ADAP Looking forward to earnings for an offical update on the progress of commercialization and royality payments from $GLPG!
DonCorleone77
Posted - 2 weeks ago
$GLPG Galapagos to present data on CAR T-cell therapy candidates GLPG5101 and GLPG5201 Galapagos announced that it will present new data from its CAR T- and TCR T-cell therapy pipeline at the 66th American Society of Hematology ASH Annual Meeting and Exposition in San Diego, CA, 7-10 December. Three abstracts, including one oral presentation, will feature new data from our proprietary cell therapy programs in relapsed/refractory non-Hodgkin lymphoma , and R/R chronic lymphocytic leukemia and Richter transformation in addition to preclinical data in head & neck cancer, developed in partnership with Adaptimmune. Galapagos will also host a company showcase, titled: Fresh, Fit, and Fast: Pioneering the Future of Cell Therapy through Decentralized Manufacturing. "We are committed to advancing breakthrough innovations to expand the reach of cell therapies for patients with rapidly progressing cancers," said Jeevan Shetty, MD, Head of Clinical Development Oncology at Galapagos. "We are excited to present promising new clinical data for our CD19 CAR T-cell therapy candidates, which continue to support the hypothesis that delivering fresh, fit cells quickly could improve outcomes for patients. Additionally, the preclinical proof-of-concept data we will present with our partner Adaptimmune highlight the potential of our innovative approach in treating solid tumors, expanding our reach to critically-ill patients beyond hematological cancers."
dhovekamp42
Posted - 2 weeks ago
$ADAP $GLPG presented at #ASH2024 Adaptimmune uza-cel potency-enhanced T-cells produced on Galapagos GDM decentralized platform in ~1 week
sjaak38
Posted - 2 weeks ago
$GLPG
sjaak38
Posted - 2 weeks ago
$GLPG
ChessGM
Posted - 10/28/24
$GLPG Upcoming Earnings Alert for 10/30/2024 Bullish (8.0) Galapagos NV has recently made significant strides in its corporate governance and shareholder engagement, highlighted by the appointment of Oleg Nodelman to its Board of Directors. This move aligns with the company's Forward, Faster strategy, aimed at enhancing operational efficiency and driving strategic growth initiatives. Financially, Galapagos is positioned favorably with a P/E ratio that remains competitive within the biotechnology sector, suggesting that the stock is reasonably valued relative to its earnings potential. The company has demonstrated robust EPS growth, indicative of its ability to enhance profitability over time, with forecasts showing a positive trajectory in revenue driven by ongoing clinical trials and drug development activities. When compared to industry peers, Galapagos exhibits advantageous metrics, particularly in terms of innovation pipeline and market positioning, which could translate into future revenue streams. Looking ahead, Galapagos is preparing for its upcoming earnings report, where analysts expect to see continued growth in both revenue and earnings per share. Historical performance has shown a pattern of meeting or exceeding analyst estimates, adding to investor confidence. The consensus among analysts suggests that the company is likely to report an EPS of approximately €1.25, reflecting a year-over-year increase. This positive outlook is underpinned by expanding partnerships and advancements in key therapeutic areas, which are expected to enhance the company’s market presence and profitability. As such, the implications of the forthcoming earnings report could be significant, with the potential to bolster the stock's valuation and align with the bullish sentiment currently observed in market analyses. - Funds were net buyers of $GLPG during the previous reporting quarter. - Top 5 funds with large holdings in $GLPG: * EcoR1 Capital LLC $143MM. CGMRank: 58% * BVF Partners LP $39MM. CGMRank: 80% * Deerfield Management Co $35MM. CGMRank: 76% * Prosight Manage $33MM. CGMRank: 55% * Stonepine Capital Management LLC $12MM. CGMRank: 56% - Last 10 days performance: -6% - Last 30 days performance: -1% - Last 90 days performance: 5% Follow ChessGM! Do not miss timely earnings alerts from ChessGM. Not a financial advice.
ThePhenix
Posted - 4 weeks ago
@Bionco Maybe. But not in $ADAP hands. They've sold the larger indications to $GLPG. $ADAP is left with double biomarker selected PROC- small numbers.
Fingerlickengood
Posted - 1 month ago
$ADAP $GLPG Update coming VERY soon! Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO) https://clinicaltrials.gov/study/NCT03967223?tab=history&a=32#version-content-panel
Fingerlickengood
Posted - 1 month ago
$ADAP $GLPG Looks like it is now officially listed. https://secure.medicalletter.org/TML-article-1713i
Fingerlickengood
Posted - 1 month ago
$ADAP $GLPG "Fox Chase is working to become an authorized treatment center for Tecelra, and von Mehren said she would recommend it if she had a patient who qualified to get the drug. "I think it provides a meaningful benefit." https://medicalxpress.com/news/2024-10-philadelphia-biotech-kind-therapy-rare.html
Noobnr1
Posted - 1 month ago
$PFE FDA Approval!!! 👏🍾🚀
Hympavzi medecin for hemofille A and B
$GILD $DVAX $PHAR $GLPG come on show us also some news 🐇💉💊💎
Fingerlickengood
Posted - 1 month ago
$ADAP $GLPG so are they actively conducting R&D with ACRO Biosystems? “ACRO Biosystems offers an extensive range of TCR-related antigen MHC-antigen peptide complexes, such as cancer-testis antigens, tissue differentiation antigens, mutation-associated neoantigens, and viral antigens. These complexes are readily available in monomer, tetramer, and fluorescent-labeled forms, as well as several different HLA subtype backbones. They incorporate native conformations, exceptional stability, and high bioactivity verified through flow cytometry, and they bind particularly well with corresponding TCRs with high affinity, fully aiding your TCR-T drug research process.” https://www.news-medical.net/whitepaper/20241009/How-Tecelrac2ae-approval-is-transforming-TCR-T-cell-therapy.aspx
Fingerlickengood
Posted - 1 month ago
$ADAP $GLPG